Download PK report

Download SIM report


Amikacin dose selection has been created for personal use only. The use of any result generated by this application is in any case the sole risk and responsibility of the user. Therapeutic decision should not solely rely on this applicatoin as the information provided by this tool does not replace clinical judgement. Amikacin dose selection has been validated and realeased in January 2019, there is no guarantee for the accuracy of the provided results. When using Amikacin dose selection you automatically agree with this disclaimer and the legal notices.


The author reserves the right not to be responsible for the topicality, correctness, completeness or quality of the information provided. Liability claims regarding damage caused by the use of any information provided, including any kind of information which is incomplete or incorrect, will therefore be rejected. All offers are not-binding and without obligation. Parts of the pages or the complete publication including all offers and information might be extended, changed or partly or completely deleted by the author without separate announcement.


The author intended not to use any copyrighted material for the publication or, if not possible, to indicate the copyright of the respective object. The copyright for any material created by the author is reserved. Any duplication or use of objects such as images, diagrams, sounds or texts in other electronic or printed publications is not permitted without the author's agreement.

PK model

A one-compartment model with linear elimination best describe amikacin time-concentration data. Serum albumin and total bodyweight were included in the amikacin clearance. Concomitant administration of vancomycin and CKD-EPI were included in amikacin clearance. Additional details of the PopPK model development and evaluation are available in the following publications: Perez-Blanco JS, Saez Fernandez EM, Lanao J, Calvo MV, Martin-Suarez A. Amikacin initial dosage in patients with hypoalbuminemia: an interactive tool based on a population pharmacokinetic approach. 2020. Journal of Antimicrobial Chemotherapy, DOI: 10.1093/jac/dkaa158

CL(L/h) = 0.525 + 4.78 x (CKD-EPI/98) x (0.77 x VANCOMYCIN)

V(L) = 26.3 x (ALBUMIN/2.9)-0.51 x [1 + 0.006 x (WGT - 70)]

Where CKD-EPI is the renal function calculated with CKD-EPI equation and expressed in mL/min (deindexed); VANCOMYCIN is 0 or 1 in abcense or co-medication with vancomycin, respectively; ALBUMIN is expresed in g/dL; WGT is total bodyweight in kg.

Important considerations which must be taking into account when applying AMKdose:

  • PopPK model was developed in adults with no acute renal impairment (<30 mL/min)
  • PKPD modifications in presence of drugs which may affect amikacin PK (i.e. meropenem, piperacillin, tigecycline, quinolone, vasoactives, etc.) were not considered in the PK model development and must be taking into account in the clinical practice
  • AMKdose has been designed as a useful tool for INITIAL dose recommendation; individual patient dosage optimization may be required based on following therapeutic drug monitoring and/or clinical response
  • Total bodyweight (TBW) was the best size descriptor of amikacin PK; however, PK alterations in morbid obesity was not studied andherefore initial dose recommendation on this population (based on TBW) may considered carefully
  • PKPD cut-offs and dose selection algorithm implemented has been chosen based on previous knowledge, but it has not been quantitatively evaluated in the literature
  • AMKdose has not been clinically validated

Salamanca, 23th July 2020

About us

We are a group of pharmacometrics who work closely with the clinical teams to improve the current treatments.

You can find us at the Pharmaceutical Science Department of the University of Salamanca (Spain).

We are also part of the Clinic and experimental pharmacokinetics group of the Biomedicine research institute of Salamanca, IBSAL.

Jonás Samuel Pérez-Blanco

email | Diarium | ORCID

Contact us

  • Do you have a question regarding this research?
  • Do you want to know how interpret the results of AMKdose?
  • Do you want to colaborate with us?
  • Do you want to get in touch with us?

Don´t hesitate to send us an email to